Media stories about Peregrine Pharmaceuticals (NASDAQ:PPHM) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3830665157493 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

PPHM has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th. BidaskClub upgraded shares of Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 17th. Noble Financial initiated coverage on shares of Peregrine Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $10.00 price target on the stock. Finally, ValuEngine lowered shares of Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Peregrine Pharmaceuticals (PPHM) traded down $0.17 during trading hours on Monday, reaching $4.40. 142,690 shares of the company’s stock were exchanged, compared to its average volume of 268,589. Peregrine Pharmaceuticals has a one year low of $1.97 and a one year high of $5.78.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last issued its quarterly earnings results on Monday, September 11th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.06. The company had revenue of $27.08 million for the quarter, compared to analyst estimates of $15.22 million. Peregrine Pharmaceuticals had a negative net margin of 23.15% and a negative return on equity of 38.19%. sell-side analysts anticipate that Peregrine Pharmaceuticals will post -0.43 EPS for the current fiscal year.

In related news, Director Mark R. Bamforth acquired 50,000 shares of the stock in a transaction dated Friday, October 27th. The stock was acquired at an average cost of $4.50 per share, with a total value of $225,000.00. Following the completion of the transaction, the director now owns 200 shares in the company, valued at approximately $900. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 4.85% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Peregrine Pharmaceuticals (PPHM) Share Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-peregrine-pharmaceuticals-pphm-share-price/1683625.html.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Insider Buying and Selling by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.